03.05.2018 • News

Chandra Asri Awards Petchem Complex Contracts

Chandra Asri Awards Petchem Complex Contracts (c) George Clerk/Getty Images
Chandra Asri Awards Petchem Complex Contracts (c) George Clerk/Getty Images

Indonesia’s largest integrated petrochemical company, Chandra Asri Petrochemical (CAP), has awarded six technology license and engineering contracts for its proposed second petrochemical complex. CAP said the awards are a significant milestone in its plan to expand its petrochemical footprint.

The company has selected technology from the following companies: CB&I for the naphtha cracker and butadiene plants; GTC Technology for aromatics (benzene, toluene and xylenes); Texplore for HDPE; and LyondellBasell for LDPE and PP.

The multi-billion dollar facility will be located adjacent to an existing complex in Cilegon and will comprise a 1.1 million t/y ethylene cracker and plants producing 600,000 t/y of propylene, 175,000 t/y butadiene, 363,000 t/y benzene, 450,000 t/y HDPE, 300,000 t/y LDPE and 450,000 t/y PP.

In April 2017, CAP set up a wholly owned subsidiary, Chandra Asri Perkasa (CAP2), to undertake a feasibility study on the complex, which is anticipated to cost around $4-5 billion.

CAP said that once the second complex is fully operational, it will be better able to meet Indonesia’s demand for petrochemicals, which is heavily reliant on imports. A timescale for the project has not been revealed.

 

 

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read